AZN.UK

10,766

+0.71%↑

GSK

1,511

-0.07%↓

INDV

1,012

+2.12%↑

AZN.UK

10,766

+0.71%↑

GSK

1,511

-0.07%↓

INDV

1,012

+2.12%↑

AZN.UK

10,766

+0.71%↑

GSK

1,511

-0.07%↓

INDV

1,012

+2.12%↑

AZN.UK

10,766

+0.71%↑

GSK

1,511

-0.07%↓

INDV

1,012

+2.12%↑

AZN.UK

10,766

+0.71%↑

GSK

1,511

-0.07%↓

INDV

1,012

+2.12%↑

Search

Hikma Pharmaceuticals PLC

Închisă

SectorSănătate

2,120 0.66

Rezumat

Modificarea prețului

24h

Curent

Minim

2118

Maxim

2126

Indicatori cheie

By Trading Economics

Venit

-93M

133M

Vânzări

-11M

1.6B

P/E

Medie Sector

18.05

51.198

EPS

1.27

Randament dividend

2.87

Marjă de profit

8.537

Angajați

9,500

EBITDA

-211M

288M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+16.58% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

2.87%

2.40%

Următoarele câștiguri

7 aug. 2025

Următoarea dată ex-dividende

14 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-351M

4.7B

Deschiderea anterioară

2119.34

Închiderea anterioară

2120

Sentimentul știrilor

By Acuity

39%

61%

126 / 380 Clasament în Healthcare

Hikma Pharmaceuticals PLC Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

8 apr. 2025, 08:20 UTC

Market Talk

Med-Tech Investors Seek 'Safe Havens' Amid Tariff Fears -- Market Talk

Comparație

Modificare preț

Hikma Pharmaceuticals PLC Așteptări

Obiectiv de preț

By TipRanks

16.58% sus

Prognoză pe 12 luni

Medie 2,480.83 GBX  16.58%

Maxim 2,650 GBX

Minim 2,000 GBX

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruHikma Pharmaceuticals PLC - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

6 ratings

5

Cumpărare

1

Păstrare

0

Vânzare

Sentiment

By Acuity

126 / 380 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.